What is the Intrinsic Value of MARKSANS PHARMA -Sep 23,2021|Fundamental Analysis

Ratio	Consolidated
P/E P/B P/S	12.01 P/E Calculated based on EPS of 5.76 [ Mar2021 - Consolidated Results ] 3.19 P/B Calculated based on Book Value of 21.66 [ Mar2021 - Consolidated Results ] 2.03 P/S Calculated based on Revenues of 1393.99 Cr [ TTM - Consolidated Results ]

Model	Discount(-)/ Premium(+)
EV/EBIDTA EV/Sales Price/Sales	-42% 19% 38%

Year	Debt/Equity ratio
	Standalone	Consolidated
2021 2020 2019 Avg_3yrs	0 0 0.17 0.06	0.02 0.03 0.18 0.08
[Last Annual Data : Mar2021]

Pledged Shares	0 %
As on : Jun2021
If less than 25%	Good
If between 25% and 50%	Neutral
If greater than 50%	Bad

Consolidated	Q-o-Q	Y-o-Y
Revenue Op Profit Profit Before Tax Profit After Tax	5.68% -18.91% -23.08% -21.26%	5.38% 10.45% 21.79% 26.81%
QtrlyTrend	2
Latest Qtr: Jun2021

BSE Indices	1W	1M	1Y
S&P BSE ALLCAP	-0.8%	7.7%	56.2%
S&P BSE MIDSMALLCAP	-1.2%	10.8%	71.8%
S&P BSE SMALL CAP	-1.6%	9.9%	78.4%
S&P BSE HEALTHCARE	-1.7%	3.6%	33.9%

#15A, 4th Floor, City Vista, Tower A,
Suite No.984, Fountain Road,
Kharadi, Pune - 411014

Contact Us
support@smart-investing.in

Smart-Investing.in
Pricing Video Course Blog

Explore
Top Gainers & Losers Quarterly Result Analysis BSE & NSE Indices

Tools
Screener Compare Analyze Portfolio

Disclaimer
The information on this site is for educational purposes only and is not investment/trading advice/research and may be delayed. We don't make any Buy/Sell recommendations and don't give any price targets. This tool provides statistical summaries of financial data in easy to understand visual form for informational purpose only. Please do your own research before making any investment decisions.

Equity investments are volatile and high risk in nature. Don't invest more than what you can afford to lose. Past Performance is not indicative of future returns.
We have affiliate relationships with Amazon and Zerodha.

Financial Data Source: Accord Fintech | Methodology | Privacy Policy | Terms & Conditions |
SEBI Registered Research Analyst Registration No : INH000007377 | Disclosure

Disclosure

Smart-Investing.in is a venture by Mr. Rohit Katiyar (henceforth referred to as the founder) who is a SEBI registered Research Analyst under the SEBI (Research Analyst) Regulations with registration number INH000007377.

Business Activities
- Apart from working on this website, the founder also works in an Ed-Tech startup in sales/marketing role.

List of Associates/Relatives:
1. Spouse : Mrs. Akanksha Singh

Disclosure with regards to ownership and material conflicts of interest:
- The founder/associates/relatives may have a financial interest in this/these stocks as retail investors themselves.
- The founder/associates/relatives don't have actual/beneficial ownership of one percent or more in these securities.
- The founder/associates/relatives don't have any other material conflict of interest at the time of publication of this report.

Disclosure with regards to receipt of compensation:
- The founder/associates/relatives have not received any compensation from the subject company in the past twelve months.
- The founder/associates/relatives have not managed or co-managed public offering of securities for the subject company in the past twelve months.
- The founder/associates/relatives have not received any compensation for investment banking/merchant banking/brokerage services/other products & services from the subject company in the past twelve months.
- The founder/associates/relatives have not received any compensation from the subject company or any 3rd party in connection with the analysis shown on the website.
- The founder is associated with Amazon and Zerodha as an affiliate and hence may be compensated for Books sold / new demat accounts opened via our platform.

General Disclosures:
- The subject companies were not our clients in any capacity in the past twelve months.
- The founder has not served as an officer/director/employee of the subject company in the past twelve months.
- The founder has not engaged in market making activity for the subject company in the past twelve months.

Disciplinary History:
-There is no disciplinary action which is / was running / initiated against the founder and there are no outstanding litigations against the founder.

WAIT.. DON'T YOU WANT FREE STUFF?

Get 20 FREE Stock Searches 🏆 &
an Awesome Investor CHECKLIST ✅ !

PLEASE DONT GO

Get UNLIMITED ACCESS !

You have only 5 Stock Searches left!

Get Unlimited Stock Searches &
Access to Advanced Features ✅ !

😀 Unlimited Stock Searches
✅ Industry Screener
✅ Fundamental Screener
✅ Portfolio Strategies
✅ Early Access to New Features

Companies in Scope

Presently, we are covering analysis for 2100+ stocks for which we have sufficient data to perform the fundamental and valuation analysis and whose Market cap is more than Rs 50 Cr.

The latest IPOs are added after a period of atleast 6 months from listing, once the quarterly results are available.

The list of all covered stocks can be seen here.

1M Sharpe Ratio Weekly Trend

Fundamental Analysis

Fundamental Score of the company compares the financial strength of the company with it's Industry peers as well as other companies in the stock market.

Fundamental Score is derived based on the statistical analysis of 5+ years historical data for consistency, drift and industry outperformance of underlying attributes listed below:

1. Company size based on Revenues. Learn More
2. Growth based on Revenues . Learn More
3. Profit Margins. Learn More
4. Return on Capital Employed (ROCE). Learn More
5. Debt Ratios. Learn More
6. Return on Equity (ROE)
7. NPA / Advances Ratio (Banks)
8. Net Interest Margin (Banks)
9. Operating Cash flow / Sales ratio
Please check the Financials tab for more information.

The Fundamental Scores are updated once the Annual Reports are published. Since there is a 1 year gap between two Annual Reports, TTM (derived from last 4 Quarterly Results) is used to provide more accuracy where available.

Valuation Analysis

Valuation Score of the company compares the current market value with the estimated intrinsic/fair value of the business as compared to other companies. The estimated fair value has been calculated based on three models:

1. Median Enterprise Value to EBIDTA model calculated over last 12 years data (where available).
Enterprise Value = Market Cap + Debt - Cash. Learn More

2. Median Enterprise Value to Sales model calculated over last 12 years data (where available).
Enterprise Value = Market Cap + Debt - Cash. Learn More

3. Median Price to Sales model calculated over last 12 years data (where available). This model is useful to analyze no profit companies. Learn More

Estimated Intrinsic Value Analysis

This section compares the current market price of the stock with the estimated Intrinsic value of the stock calculated based on 3 Valuation models described in the Valuation section.

If Intrinsic Value (Enterprise Value/EBIDTA Model) is -ve, the company made a loss in last financial year or had a high debt.

If Intrinsic Value (Enterprise Value/Sales Model) is -ve, the company had a high debt in the last financial year.

If Intrinsic Value (EV/Sales OR Price/Sales Model) is 0, the latest data is not available.

In general, there are 2 methods to estimate the fair value of a stock.
1. Relative Valuation (used by us) and
2. Absolute Valuation (DCF).

Both methods have their pros and cons and there is nothing right or wrong. Eg. DCF method depends hugely on the assumptions for future growth rate and discount rate which can vary depending on a person's outlook.

Net NPA/Advances ratio analysis

For Banking industry,
Good = Ratio less than 0.5
Average = Ratio between 0.5 and 1
Bad = Ratio greater than 1

Debt/Equity ratio analysis

For all non-Banking industries,
Good = Ratio less than 0.4
Average = Ratio between 0.4 and 0.6
Bad = Ratio greater than 0.6

Worst is considered between Standalone & Consolidated

Quarterly Trend analysis

The growth rate scores are assigned as under:
If ratio's 1Q growth is +ve, then 1. If -ve, then -1.
If ratio's 4Q growth is +ve, then 1.If -ve, then -1.

Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income.

Interpretation
Good = Growth Score >=4
Neutral = Growth Score between 0 and 4
Bad = Growth Score less than 0

Long Term Analysis

The long term FVD (Fundamentals - Valuation - Debt) Squares represent long term view for a company based on Annual Earnings, Valuation and Debt of the stock. This summary is suitable for Investors investing in the market with a time horizon of more than 3 years. For Banks, NPA/Advances ratio is considered instead of Debt.

Good
Average
Bad

Short Term Analysis

The short term QPP (Quarterly Earnings Trend- Price Momentum - Pledged Shares) Squares represent short term view for a company which is suitable for Traders taking positions in the market with a time horizon of less than 3 years .

Good
Average
Bad

Peers & Returns	1W	1M	1Y
MARKSANS PHARMA	-1.9%	2%	38%
SUN PHARMACEUTICAL INDUSTRIES	-2%	0.5%	49.5%
DIVIS LABORATORIES	-0.3%	5.6%	59.6%
DR REDDYS LABORATORIES	-1.7%	7.3%	4.8%
CIPLA	1.1%	7.4%	27%
GLAND PHARMA	-3.9%	-2.3%	NA
PIRAMAL ENTERPRISES	-1.4%	-1%	85.9%
CADILA HEALTHCARE	-2.8%	2.8%	45.7%
TORRENT PHARMACEUTICALS	-2.7%	-0.1%	10.7%

MARKSANS PHARMA
Intrinsic Value | Fundamental Analysis

Check out Industry Peers

FUNDAMENTAL ANALYSIS OF MARKSANS PHARMA

VALUATION OF MARKSANS PHARMA

FAIR VALUE OF MARKSANS PHARMA

SHARE PRICE MOMENTUM OF MARKSANS PHARMA

DEBT

PLEDGED SHARES

QTRLY RESULTS

MARKSANS PHARMA related INDICES

FAQ [Frequently Asked Questions]

Is MARKSANS PHARMA good for long term investment?

Is MARKSANS PHARMA UnderValued or OverValued?